A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Research & Development, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological proof of non-metastatic muscle-invasive urothelial cell carcinoma of the bladder
Participant must have been as fully resected as possible per the physician's judgment
Participants must be deemed unfit for RC due to comorbid conditions with a risk of mortality
Participants must refuse or be deemed ineligible for cisplatin-based chemotherapy
Participant must refuse or not be eligible for radiotherapy
You may not be if
Other active malignancies
Presence of any bladder or urethral anatomic feature that in the opinion of the Investigator may prevent the safe placement, indwelling use, or removal of TAR-200
Pyeloureteral tube externalized to the skin (ureteral stent or unilateral nephrostomy tube is allowed)
Evidence of bladder perforation during diagnostic cystoscopy
Concurrent clinically significant infections as determined by the treating Investigator
Clareo Health | A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
